GSK settles two California lawsuits related to heartburn drug Zantac
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...
GSK, iTeos Lung Cancer Data Set to Reignite Hope for Drug Class
Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious ...
STAT7d
Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...
GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
Teos (ITOS) stock is in focus as experimental cancer doublet therapy, developed with GSK, outperformed Jemperliin a mid-stage ...
Morningstar8d
GSK Bets on Blood-Cancer Drug Comeback Amid Oncology Push
GSK is betting that Blenrep--a blood-cancer treatment that U.S. drug regulators asked it to pull from the market in 2022--could get a second chance, part of a push by the British pharma giant to ...
FiercePharma7d
ESMO: GSK's Zejula misses survival goal in first-line ovarian cancer, as pharma&'s combo disappoints
In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...
Japan to review GSK's Blenrep drug application
Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for the drug.
Pharmaceutical Technology12d
Dostarlimab by GSK for Vaginal Cancer: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...